Apollo Hospitals Enterprise
- Market Cap
- ₹1,32,282 Cr
- P/E
- 59.00
Key Fundamentals
LargecapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 17.40%
- Debt to Equity
- 0.77
- EPS (TTM)
- ₹155.94
- Book Value
- ₹737.49
- Market Cap
- ₹1,32,282 Cr
- P/E (TTM)
- 59.00
- P/B
- 12.47
- ROE
- 21.50%
- Dividend Yield
- 0.23%
- EBITDA
- ₹3,961 Cr
- 52W High
- ₹9,282.50
- 52W Low
- ₹6,696.50
- Day Range
- ₹8,800.00 – ₹9,282.50
- Volume
- 14,12,562
Peer Comparison
Healthcare › Healthcare Services › Hospital
| 9,200.00 | 59.00 | 1,32,282 | 12.47 | 0.23% | 21.50% | 17.40% | 27,630 | 2,337 | |
| 1,081.00 | 76.23 | 1,05,215 | 9.28 | 0.20% | 14.70% | 14.70% | 9,146 | 1,380 | |
| 702.20 | 101.77 | 92,366 | 6.01 | 0.00% | 6.72% | 8.30% | 12,370 | 873 | |
| 779.30 | 110.70 | 67,929 | 8.72 | 0.41% | 11.30% | 11.60% | 6,508 | 564 | |
| 825.00 | 59.96 | 62,284 | 5.94 | 0.13% | 11.20% | 13.40% | 9,910 | 1,061 | |
| 1,480.20 | 64.33 | 39,798 | 9.20 | 0.03% | 15.20% | 17.40% | 5,053 | 613 | |
| 1,943.70 | 46.25 | 39,722 | 7.94 | 0.24% | 20.50% | 15.50% | 10,273 | 859 | |
| Median 7 companies | 1,081.00 | 64.33 | 67,929 | 8.72 | 0.20% | 14.70% | 14.70% | 9,910 | 873 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 50
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 56
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 27
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 24
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has delivered good profit growth of 76.8% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 17.7%
Weaknesses
2- Stock is trading at 12.5 times its book value
- Company might be capitalizing the interest cost
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 4 | 2 | 13 |
| Oscillators | Bearish | 4 | 2 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 70.74
- Bearish
- MACD (12,26,9)
- 185.51
- Bullish
- SMA (50)
- 8,384.71
- Bullish
- SMA (200)
- 8,212.45
- Bullish
As of
Analyst Rating
23 of 27 analysts rate Buy, 3 Hold, 1 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +15.16% |
|---|---|
| 5Y | +19.03% |
| 3Y | +14.94% |
| 1Y | +15.76% |
| TTM | +19.35% |
Net profit
| 10Y | +23.90% |
|---|---|
| 5Y | +71.00% |
| 3Y | +33.39% |
| 1Y | +33.09% |
| TTM | +35.24% |
Operating cash flow
| 10Y | +16.94% |
|---|---|
| 5Y | +17.69% |
| 3Y | +27.53% |
| 1Y | +33.71% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +3.86 pp |
|---|---|
| 5Y | +4.18 pp |
| 3Y | +2.55 pp |
| 1Y | +1.06 pp |
| TTM | +1.07 pp |
Revenue by year
| Mar 2017 | ₹7,256 Cr |
|---|---|
| Mar 2018 | ₹8,243 Cr |
| Mar 2019 | ₹9,617 Cr |
| Mar 2020 | ₹11,247 Cr |
| Mar 2021 | ₹10,560 Cr |
| Mar 2022 | ₹14,663 Cr |
| Mar 2023 | ₹16,612 Cr |
| Mar 2024 | ₹19,059 Cr |
| Mar 2025 | ₹21,794 Cr |
| Mar 2026 | ₹25,228 Cr |
Net profit by year
| Mar 2017 | ₹131 Cr |
|---|---|
| Mar 2018 | ₹60.00 Cr |
| Mar 2019 | ₹200 Cr |
| Mar 2020 | ₹432 Cr |
| Mar 2021 | ₹137 Cr |
| Mar 2022 | ₹1,108 Cr |
| Mar 2023 | ₹844 Cr |
| Mar 2024 | ₹935 Cr |
| Mar 2025 | ₹1,505 Cr |
| Mar 2026 | ₹2,003 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Apollo Hospitals Enterprise Ltd trades at ₹8,738 as of 2026-11-19, commanding a market cap of ₹1,25,639 Cr with a P/E (TTM) of 56.03 and ROE of 20.08%. The company has demonstrated strong profit compounding at 77% CAGR over five years alongside 19% TTM sales growth, though the stock trades at 11.85 times book value and carries a debt-to-equity ratio of 0.9.
- Exceptional five-year compounded profit growth of 77% CAGR reflects a sharp improvement in earnings power across hospital and digital health segments
- TTM profit growth of 35% indicates continued strong momentum in the most recent period, well above the 10-year compounded profit growth rate of 24%
- ROE of 20.08% as of 2026-11-19, with the last-year ROE at 21%, represents a meaningful step-up from the 10-year average ROE of 13%, signalling improved capital efficiency
- Compounded sales growth of 19% on a TTM basis matches the five-year CAGR of 19%, suggesting revenue momentum has been sustained rather than front-loaded
- Ten-year compounded sales growth of 15% demonstrates durable, long-term demand for the company's healthcare services across economic cycles
- The stock has delivered a 10-year price CAGR of 22%, reflecting long-term wealth creation through both business growth and re-rating
- The company has maintained a healthy dividend payout ratio of 17.7%, providing a degree of capital return discipline despite being in a growth phase
- Trading at ₹8,738 against a 52-week low of ₹6,696.50, the stock has recovered roughly 30% from its annual trough, indicating resilient investor confidence
- A trailing P/E of 56.03 is well above the broader market average, requiring sustained high earnings growth to justify the premium valuation
- Debt-to-equity ratio of 0.9 is notable for a hospital business; combined with concerns that the company might be capitalising interest costs, the true leverage picture warrants scrutiny
- Dividend yield of just 0.23% offers negligible income support, meaning returns depend almost entirely on capital appreciation
- The three-year stock CAGR of 17% and five-year stock CAGR of 9% lag the 10-year CAGR of 22%, suggesting the pace of market re-rating may be decelerating
- Three-year compounded sales growth of 15% has not accelerated versus the 10-year rate of 15%, indicating revenue growth may be approaching a steady state rather than inflecting higher
- ROCE of 19.79% trails the ROE of 20.08% only marginally, but the gap could widen if debt-funded expansions do not generate proportionate returns
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Apollo Hospitals delivered a strong Q2FY27 with 32% profit growth and 23% revenue expansion, reflecting robust demand across core specialties and international patient services. No notable headwinds emerged in the period's coverage. The growth trajectory remains firmly positive, though sustaining this pace will depend on continued volume momentum and margin discipline in coming quarters.
- Q2FY27 PAT surges 32% YoY Nov 4
Consolidated PAT rose 32% YoY to ₹630 crore in Q2FY27. Revenue grew 23% YoY to ₹7,615 crore, driven by strong volume growth in core specialties and international services.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,847 | 4,851 | 4,944 | 5,086 | 5,589 | 5,527 | 5,592 | 5,842 | 6,189 | 6,477 | 6,606 | 6,932 | 7,615 |
| Expenses | 4,219 | 4,237 | 4,303 | 4,410 | 4,774 | 4,765 | 4,822 | 4,990 | 5,264 | 5,512 | 5,594 | 5,855 | 6,424 |
| Operating Profit | 628 | 614 | 640 | 675 | 816 | 762 | 770 | 852 | 924 | 965 | 1,011 | 1,077 | 1,191 |
| OPM % | 13% | 13% | 13% | 13% | 15% | 14% | 14% | 15% | 15% | 15% | 15% | 16% | 16% |
| Other Income | 26 | 29 | 37 | 49 | 44 | 69 | 72 | 54 | 54.7 | 48 | 54 | 52 | 58 |
| Interest | 111 | 113 | 119 | 116 | 118 | 110 | 115 | 108 | 99 | 113 | 119 | 108 | 114 |
| Depreciation | 163 | 167 | 190 | 177 | 184 | 185 | 211 | 215 | 205 | 219 | 224 | 222 | 230 |
| PBT | 379 | 363 | 368 | 430 | 557 | 536 | 516 | 583 | 675 | 682 | 722 | 799 | 904 |
| Tax % | 34% | 30% | 30% | 27% | 29% | 29% | 20% | 24% | 27% | 24% | 24% | 24% | 27% |
| Net Profit | 249 | 254 | 258 | 316 | 396 | 379 | 414 | 441 | 494 | 516 | 551 | 610 | 660 |
| EPS (₹) | 16.20 | 17.06 | 17.65 | 21.23 | 26.34 | 25.89 | 27.10 | 30.10 | 33.19 | 34.93 | 36.81 | 40.39 | 43.81 |
| YoY Sales growth | 14 | 14 | 15 | 15 | 15 | 14 | 13 | 15 | 11 | 17 | 18 | 19 | 23 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,129 | 6,150 | 7,256 | 8,243 | 9,617 | 11,247 | 10,560 | 14,663 | 16,612 | 19,059 | 21,794 | 25,228 | 27,630 |
| Expenses | 4,392 | 5,465 | 6,522 | 7,442 | 8,548 | 9,656 | 9,420 | 12,474 | 14,548 | 16,665 | 18,761 | 21,449 | 23,386 |
| Operating Profit | 737 | 684 | 734 | 801 | 1,070 | 1,591 | 1,140 | 2,189 | 2,065 | 2,394 | 3,033 | 3,779 | 4,244 |
| OPM % | 14% | 11% | 10% | 10% | 11% | 14% | 11% | 15% | 12% | 13% | 14% | 15% | 15% |
| Other Income | 47 | 92 | 60 | 24 | 26 | 222 | 103 | 368 | 75 | 123 | 222 | 207 | 213 |
| Interest | 118 | 180 | 257 | 295 | 327 | 533 | 449 | 379 | 381 | 449 | 458 | 450 | 454 |
| Depreciation | 212 | 264 | 314 | 359 | 396 | 620 | 573 | 601 | 615 | 687 | 758 | 876 | 896 |
| PBT | 455 | 332 | 222 | 171 | 373 | 660 | 221 | 1,578 | 1,144 | 1,380 | 2,039 | 2,661 | 3,107 |
| Tax % | 29% | 29% | 41% | 65% | 47% | 34% | 38% | 30% | 22% | 32% | 26% | 25% | — |
| Net Profit | 335 | 235 | 131 | 60 | 200 | 432 | 137 | 1,108 | 844 | 935 | 1,505 | 2,003 | 2,338 |
| EPS (₹) | 24.43 | 16.99 | 15.88 | 8.44 | 16.96 | 32.70 | 10.46 | 73.42 | 56.97 | 62.50 | 100.56 | 135.04 | 155.94 |
| Div. Payout % | 24% | 35% | 38% | 59% | 35% | 18% | 29% | 16% | 26% | 26% | 13% | 15% | — |
| Sales growth | 18 | 20 | 18 | 14 | 17 | 17 | −6 | 39 | 13 | 15 | 14 | 16 | 19 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 70 | 70 | 70 | 70 | 70 | 72 | 72 | 72 | 72 | 72 | 72 | 72 |
| Reserves | 3,102 | 3,262 | 3,244 | 3,182 | 3,264 | 3,270 | 4,531 | 5,551 | 6,126 | 6,864 | 8,140 | 9,408 | 10,532 |
| Borrowings | 1,992 | 2,834 | 3,125 | 3,427 | 3,673 | 3,596 | 4,160 | 4,068 | 4,332 | 5,333 | 7,864 | 8,493 | 8,149 |
| Other Liabilities | 1,296 | 1,195 | 1,665 | 1,917 | 2,159 | 4,354 | 2,629 | 3,570 | 3,886 | 4,474 | 4,568 | 4,210 | 5,469 |
| Total Liabilities | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 22,183 | 24,222 |
| Fixed Assets | 3,244 | 3,997 | 4,591 | 4,773 | 4,982 | 7,432 | 6,778 | 8,296 | 8,520 | 9,664 | 10,988 | 12,272 | 12,246 |
| CWIP | 533 | 562 | 347 | 712 | 822 | 236 | 234 | 46 | 610 | 873 | 921 | 1,032 | 1,494 |
| Investments | 311 | 352 | 406 | 352 | 462 | 434 | 1,343 | 816 | 574 | 986 | 2,487 | 2,179 | 2,192 |
| Other Assets | 2,372 | 2,448 | 2,759 | 2,759 | 2,901 | 3,187 | 3,037 | 4,104 | 4,712 | 5,219 | 6,248 | 6,700 | 8,291 |
| Total Assets | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 22,183 | 24,222 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 470 | 597 | 623 | 537 | 905 | 1,293 | 1,265 | 1,696 | 1,377 | 1,920 | 2,136 | 2,856 |
| Investing | −759 | −888 | −1,152 | −405 | −711 | −289 | −880 | −747 | −857 | −1,537 | −3,383 | −2,145 |
| Financing | 392 | 330 | 477 | −108 | −215 | −910 | −340 | −792 | −633 | −311 | 1,319 | −478 |
| Net Cash Flow | 103 | 39 | −52 | 24 | −20 | 94 | 44 | 158 | −113 | 72 | 73 | 233 |
| Free Cash Flow | −396 | −393 | −46 | −84 | 233 | 782 | 984 | 1,044 | 252 | 785 | 439 | 925 |
| CFO/EBITDA | 77 | 108 | 103 | 83 | 103 | 100 | 108 | 87 | 85 | 100 | 86 | 92 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 36 | 38 | 37 | 39 | 33 | 46 | 44 | 49 | 48 | 51 | 50 |
| Inventory Days | 50 | 49 | 47 | 51 | 46 | 49 | 16 | 21 | 17 | 17 | 16 | 15 |
| Days Payable | 59 | 66 | 51 | 55 | 56 | 60 | 74 | 79 | 82 | 88 | 72 | 63 |
| Cash Conversion Cycle | 34 | 19 | 34 | 33 | 29 | 22 | −12 | −14 | −16 | −23 | −6 | 3 |
| Working Capital Days | 24 | 16 | 27 | 8 | −3 | −8 | −4 | 5 | −1 | −19 | −6 | −25 |
| ROCE % | 12% | 9% | 8% | 7% | 10% | 14% | 8% | 17% | 14% | 15% | 17% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Apollo Hospitals insights
64 extracted metrics across FY00–FY27.
Documents
- Concall · Nov 2026Transcript Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 4 Nov 2026
- 12 Aug 2026
- 12 Aug 2025
- 19 Jun 2026
- 29 May 2026
- 18 May 2026
- 23 Apr 2026
- 27 Jan 2026
- General announcements 11 Nov 2026
- General announcements 6 Nov 2026
Frequently Asked Questions about Apollo Hospitals Enterprise
What does Apollo Hospitals Enterprise Ltd do?
Where is Apollo Hospitals Enterprise Ltd (APOLLOHOSP) listed?
Which sector does Apollo Hospitals Enterprise Ltd belong to?
What is the market capitalisation of Apollo Hospitals Enterprise Ltd?
What is the PE ratio of Apollo Hospitals Enterprise Ltd?
What is the 52-week high and low of Apollo Hospitals Enterprise Ltd?
Does Apollo Hospitals Enterprise Ltd pay dividends?
What is the Return on Equity (ROE) of Apollo Hospitals Enterprise Ltd?
Company Information
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country. Apollo Hospitals has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APOLLOHOSP.md for Apollo Hospitals Enterprise Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.